König L, Lange E
Psychiatr Neurol Med Psychol Beih. 1975;20-21:164-9.
Pimozid (R 6238 Janssen, Beerse), a neuroleptic similar to the Butyrophenon type has a 24-hour period of effect due to the substance, and was used from 1969 onward on a total of 39 patients, predominantly from the range of schizophrenia types. The objective of thus clinical study was, above all, to plot the extent of its effects, define the optimal range of indications, to determine the most favourable dosage profile and to examine its tolerance in long-term use. Objectifying the medicinal effects, for example recording the psychopathological findings, proved successful with the aid of a syndrom catalogue following the AMP system, in comparison with preceeding and following treatments and considering the social-psychiatric aspects, so that concomitant- and side effects can be ascertained in the same way. The necessary maintenance dose of Pimozid, usually administered once a day, was set in relation to the daily dosage of Haloperidol, which had to be administered 2 to 3 times daily; the results, meanwhile, were compared with those already recorded on the literature. In agreement with this Pimozid proved to be a powerful and well tolerated neuroleptic, even in older patients, with a constant 24-hour effect which is suitable in doses from 1--10 mg/d particularly for long-term out-patient therapy, and above all for psychotics of the paranoid hallucinatory type.
匹莫齐特(R 6238,杨森制药公司,贝尔瑟)是一种类似于丁酰苯类的抗精神病药物,该药物的作用时长为24小时。自1969年起,共有39名患者使用了该药物,这些患者主要患有各种类型的精神分裂症。这项临床研究的主要目的是评估其疗效范围、确定最佳适应症范围、找出最适宜的剂量方案,并检验其长期使用的耐受性。借助遵循AMP系统的症状目录,对比治疗前后的情况并考虑社会精神病学方面的因素,成功实现了对药物疗效的客观化评估,例如记录精神病理学检查结果,从而能够以同样的方式确定药物的伴随效应和副作用。匹莫齐特的必要维持剂量通常为每日一次,该剂量是参照每日需服用2至3次的氟哌啶醇的剂量设定的;同时,将研究结果与文献中已记录的结果进行了比较。与此一致的是,匹莫齐特被证明是一种强效且耐受性良好的抗精神病药物,即使在老年患者中也是如此,它具有持续24小时的药效,剂量为1 - 10毫克/日时尤其适用于长期门诊治疗,特别是对于偏执幻觉型精神病患者。